- Home
- DMAC vs AVIR Comparison
DMAC vs AVIR Comparison
Compare DMAC & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- AVIR
- Stock Information
- Founded
- DMAC 2000
- AVIR 2012
- Country
- DMAC United States
- AVIR United States
- Employees
- DMAC N/A
- AVIR N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- DMAC Health Care
- AVIR Health Care
- Exchange
- DMAC Nasdaq
- AVIR Nasdaq
- Market Cap
- DMAC 310.1M
- AVIR 290.4M
- IPO Year
- DMAC N/A
- AVIR 2020
- Fundamental
- Price
- DMAC $6.97
- AVIR $2.97
- Analyst Decision
- DMAC Strong Buy
- AVIR Hold
- Analyst Count
- DMAC 3
- AVIR 1
- Target Price
- DMAC $12.33
- AVIR $6.00
- AVG Volume (30 Days)
- DMAC 443.2K
- AVIR 244.4K
- Earning Date
- DMAC 11-12-2025
- AVIR 11-06-2025
- Dividend Yield
- DMAC N/A
- AVIR N/A
- EPS Growth
- DMAC N/A
- AVIR N/A
- EPS
- DMAC N/A
- AVIR N/A
- Revenue
- DMAC N/A
- AVIR N/A
- Revenue This Year
- DMAC N/A
- AVIR N/A
- Revenue Next Year
- DMAC N/A
- AVIR N/A
- P/E Ratio
- DMAC N/A
- AVIR N/A
- Revenue Growth
- DMAC N/A
- AVIR N/A
- 52 Week Low
- DMAC $3.19
- AVIR $2.46
- 52 Week High
- DMAC $7.49
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- DMAC 66.23
- AVIR 31.20
- Support Level
- DMAC $6.83
- AVIR $3.10
- Resistance Level
- DMAC $7.41
- AVIR $3.33
- Average True Range (ATR)
- DMAC 0.42
- AVIR 0.14
- MACD
- DMAC 0.06
- AVIR -0.04
- Stochastic Oscillator
- DMAC 77.88
- AVIR 2.01
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).